0 XP   0   0   0

Advanced Oncotherapy Plc
Buy, Hold or Sell?

Should you buy, hold or sell Advanced Oncotherapy Plc?

I guess you are interested in Advanced Oncotherapy Plc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Advanced Oncotherapy Plc

Let's start. I'm going to help you getting a better view of Advanced Oncotherapy Plc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Advanced Oncotherapy Plc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Advanced Oncotherapy Plc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Advanced Oncotherapy Plc. The closing price on 2023-02-03 was p9.75 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Advanced Oncotherapy Plc Daily Candlestick Chart
Advanced Oncotherapy Plc Daily Candlestick Chart
Summary









1. Valuation of Advanced Oncotherapy Plc




Current price per share

p9.75

2. Growth of Advanced Oncotherapy Plc




Is Advanced Oncotherapy Plc growing?

Current yearPrevious yearGrowGrow %
How rich?$73.9m$53.1m$20.7m28.1%

How much money is Advanced Oncotherapy Plc making?

Current yearPrevious yearGrowGrow %
Making money-$35.5m-$30.4m-$5m-14.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Advanced Oncotherapy Plc




Comparing to competitors in the Medical Devices industry




  Industry Rankings (Medical Devices)  



Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

1.1. Profitability of Advanced Oncotherapy Plc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Advanced Oncotherapy Plc earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Advanced Oncotherapy Plc to the Medical Devices industry mean.
  • A Net Profit Margin of 0.0% means that 0.00 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Advanced Oncotherapy Plc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-1,544.1%+1,544.1%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.2%+16.2%
TTM--15.7%+15.7%
YOY--15.1%+15.1%
5Y--22.6%+22.6%
10Y-1,544.1%-24.7%-1,519.4%
1.1.2. Return on Assets

Shows how efficient Advanced Oncotherapy Plc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Advanced Oncotherapy Plc to the Medical Devices industry mean.
  • -20.9% Return on Assets means that Advanced Oncotherapy Plc generated -0.21 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Advanced Oncotherapy Plc:

  • The MRQ is -20.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -20.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.9%TTM-20.9%0.0%
TTM-20.9%YOY-20.7%-0.2%
TTM-20.9%5Y-25.2%+4.3%
5Y-25.2%10Y-31.1%+5.9%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.9%-2.9%-18.0%
TTM-20.9%-2.8%-18.1%
YOY-20.7%-2.2%-18.5%
5Y-25.2%-3.6%-21.6%
10Y-31.1%-3.5%-27.6%
1.1.3. Return on Equity

Shows how efficient Advanced Oncotherapy Plc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Advanced Oncotherapy Plc to the Medical Devices industry mean.
  • -48.1% Return on Equity means Advanced Oncotherapy Plc generated -0.48 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Advanced Oncotherapy Plc:

  • The MRQ is -48.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -48.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-48.1%TTM-48.1%0.0%
TTM-48.1%YOY-57.3%+9.3%
TTM-48.1%5Y-52.7%+4.7%
5Y-52.7%10Y-102.5%+49.8%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-48.1%-3.2%-44.9%
TTM-48.1%-3.6%-44.5%
YOY-57.3%-1.9%-55.4%
5Y-52.7%-4.0%-48.7%
10Y-102.5%-4.3%-98.2%

1.2. Operating Efficiency of Advanced Oncotherapy Plc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Advanced Oncotherapy Plc is operating .

  • Measures how much profit Advanced Oncotherapy Plc makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Advanced Oncotherapy Plc to the Medical Devices industry mean.
  • An Operating Margin of 0.0% means the company generated 0.00  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Advanced Oncotherapy Plc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-839.3%+839.3%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.2%+15.2%
TTM--14.2%+14.2%
YOY--11.0%+11.0%
5Y--20.2%+20.2%
10Y-839.3%-22.3%-817.0%
1.2.2. Operating Ratio

Measures how efficient Advanced Oncotherapy Plc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are 0.00 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of Advanced Oncotherapy Plc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y9.753-9.753
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.418-1.418
TTM-1.283-1.283
YOY-1.231-1.231
5Y-1.325-1.325
10Y9.7531.289+8.464

1.3. Liquidity of Advanced Oncotherapy Plc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Advanced Oncotherapy Plc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 1.91 means the company has 1.91 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of Advanced Oncotherapy Plc:

  • The MRQ is 1.907. The company is able to pay all its short-term debts. +1
  • The TTM is 1.907. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.907TTM1.9070.000
TTM1.907YOY1.371+0.535
TTM1.9075Y1.796+0.111
5Y1.79610Y1.868-0.072
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9073.491-1.584
TTM1.9073.832-1.925
YOY1.3713.480-2.109
5Y1.7963.545-1.749
10Y1.8683.273-1.405
1.3.2. Quick Ratio

Measures if Advanced Oncotherapy Plc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Advanced Oncotherapy Plc to the Medical Devices industry mean.
  • A Quick Ratio of 0.27 means the company can pay off 0.27 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Advanced Oncotherapy Plc:

  • The MRQ is 0.273. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.273. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.273TTM0.2730.000
TTM0.273YOY0.129+0.144
TTM0.2735Y0.309-0.036
5Y0.30910Y0.402-0.093
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2731.723-1.450
TTM0.2732.035-1.762
YOY0.1291.879-1.750
5Y0.3091.805-1.496
10Y0.4021.775-1.373

1.4. Solvency of Advanced Oncotherapy Plc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Advanced Oncotherapy Plc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Advanced Oncotherapy Plc to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.57 means that Advanced Oncotherapy Plc assets are financed with 56.6% credit (debt) and the remaining percentage (100% - 56.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Advanced Oncotherapy Plc:

  • The MRQ is 0.566. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.566. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.566TTM0.5660.000
TTM0.566YOY0.639-0.073
TTM0.5665Y0.523+0.043
5Y0.52310Y0.458+0.065
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5660.339+0.227
TTM0.5660.350+0.216
YOY0.6390.438+0.201
5Y0.5230.467+0.056
10Y0.4580.472-0.014
1.4.2. Debt to Equity Ratio

Measures if Advanced Oncotherapy Plc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Advanced Oncotherapy Plc to the Medical Devices industry mean.
  • A Debt to Equity ratio of 130.2% means that company has 1.30 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Advanced Oncotherapy Plc:

  • The MRQ is 1.302. The company is able to pay all its debts with equity. +1
  • The TTM is 1.302. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.302TTM1.3020.000
TTM1.302YOY1.770-0.468
TTM1.3025Y1.197+0.105
5Y1.19710Y1.958-0.761
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3020.462+0.840
TTM1.3020.462+0.840
YOY1.7700.581+1.189
5Y1.1970.632+0.565
10Y1.9580.688+1.270

2. Market Valuation of Advanced Oncotherapy Plc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Advanced Oncotherapy Plc generates.

  • Above 15 is considered overpriced but always compare Advanced Oncotherapy Plc to the Medical Devices industry mean.
  • A PE ratio of -6.93 means the investor is paying -6.93 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Advanced Oncotherapy Plc:

  • The EOD is -1.777. Company is losing money. -2
  • The MRQ is -6.925. Company is losing money. -2
  • The TTM is -6.925. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-1.777MRQ-6.925+5.148
MRQ-6.925TTM-6.9250.000
TTM-6.925YOY-7.648+0.723
TTM-6.9255Y-11.515+4.590
5Y-11.51510Y-11.252-0.263
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-1.777-6.306+4.529
MRQ-6.925-6.896-0.029
TTM-6.925-11.813+4.888
YOY-7.648-10.927+3.279
5Y-11.515-9.713-1.802
10Y-11.252-7.673-3.579
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Advanced Oncotherapy Plc.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Advanced Oncotherapy Plc:

  • The MRQ is -8.301. Very Bad. -2
  • The TTM is -8.301. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-8.301TTM-8.3010.000
TTM-8.301YOY-9.763+1.462
TTM-8.3015Y-16.747+8.446
5Y-16.74710Y-21.952+5.205
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.3010.013-8.314
TTM-8.3010.046-8.347
YOY-9.7630.027-9.790
5Y-16.7470.068-16.815
10Y-21.9520.047-21.999

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Advanced Oncotherapy Plc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 3.33 means the investor is paying 3.33 for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of Advanced Oncotherapy Plc:

  • The EOD is 0.854. Very good. +2
  • The MRQ is 3.328. Neutral. Compare to industry.
  • The TTM is 3.328. Neutral. Compare to industry.
Trends
Current periodCompared to+/- 
EOD0.854MRQ3.328-2.474
MRQ3.328TTM3.3280.000
TTM3.328YOY4.383-1.055
TTM3.3285Y5.949-2.621
5Y5.94910Y1.376+4.573
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD0.8542.196-1.342
MRQ3.3282.474+0.854
TTM3.3283.559-0.231
YOY4.3834.220+0.163
5Y5.9493.471+2.478
10Y1.3763.042-1.666
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Advanced Oncotherapy Plc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--3.2053.2050%0.225+1327%1.019+215%1.133+183%
Book Value Growth--1.3901.3900%1.028+35%1.142+22%5.171-73%
Book Value Per Share--11.41811.4180%8.213+39%7.855+45%5.372+113%
Book Value Per Share Growth--1.3901.3900%1.028+35%1.142+22%5.171-73%
Current Ratio--1.9071.9070%1.371+39%1.796+6%1.868+2%
Debt To Asset Ratio--0.5660.5660%0.639-11%0.523+8%0.458+23%
Debt To Equity Ratio--1.3021.3020%1.770-26%1.197+9%1.958-34%
Dividend Per Share----0%-0%-0%-0%
Eps---5.487-5.4870%-4.707-14%-4.108-25%-2.631-52%
Eps Growth--0.8340.8340%0.783+6%0.753+11%0.756+10%
Free Cash Flow Per Share---7.231-7.2310%-5.150-29%-4.986-31%-3.383-53%
Free Cash Flow Per Share Growth--0.5960.5960%1.221-51%0.719-17%0.319+87%
Free Cash Flow To Equity Per Share--0.3580.3580%-0.175+149%0.089+303%0.052+587%
Free Cash Flow To Equity Per Share Growth--4.0444.0440%-0.495+112%2.026+100%2.255+79%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--36.248--------
Intrinsic Value_10Y_min--7.125--------
Intrinsic Value_1Y_max---4.193--------
Intrinsic Value_1Y_min---5.281--------
Intrinsic Value_3Y_max---6.635--------
Intrinsic Value_3Y_min---10.770--------
Intrinsic Value_5Y_max---1.887--------
Intrinsic Value_5Y_min---10.628--------
Net Profit Margin----0%-0%-0%-15.4410%
Operating Margin----0%-0%-0%-8.3930%
Operating Ratio----0%-0%-0%9.753-100%
Pb Ratio0.854-290%3.3283.3280%4.383-24%5.949-44%1.376+142%
Pe Ratio-1.777+74%-6.925-6.9250%-7.648+10%-11.515+66%-11.252+62%
Peg Ratio---8.301-8.3010%-9.763+18%-16.747+102%-21.952+164%
Price Per Share9.750-290%38.00038.0000%36.000+6%42.200-10%30.275+26%
Price To Total Gains Ratio3.042-290%11.85611.8560%160.281-93%35.604-67%24.022-51%
Profit Growth--0.8340.8340%0.783+6%0.753+11%0.756+10%
Quick Ratio--0.2730.2730%0.129+112%0.309-12%0.402-32%
Return On Assets---0.209-0.2090%-0.207-1%-0.252+21%-0.311+49%
Return On Equity---0.481-0.4810%-0.573+19%-0.527+10%-1.025+113%
Total Gains Per Share--3.2053.2050%0.225+1327%1.019+215%1.133+183%
Total Gains Per Share Growth--14.27014.2700%0.135+10467%3.658+290%3.538+303%
Usd Book Value--73925612.96973925612.9690%53173788.079+39%50859206.277+45%34780981.601+113%
Usd Book Value Change Per Share--0.0390.0390%0.003+1327%0.012+215%0.014+183%
Usd Book Value Per Share--0.1380.1380%0.099+39%0.095+45%0.065+113%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.066-0.0660%-0.057-14%-0.049-25%-0.032-52%
Usd Free Cash Flow---46816459.781-46816459.7810%-33344785.566-29%-32284785.509-31%-21906387.372-53%
Usd Free Cash Flow Per Share---0.087-0.0870%-0.062-29%-0.060-31%-0.041-53%
Usd Free Cash Flow To Equity Per Share--0.0040.0040%-0.002+149%0.001+303%0.001+587%
Usd Price Per Share0.117-290%0.4580.4580%0.434+6%0.508-10%0.365+26%
Usd Profit---35526948.581-35526948.5810%-30475743.971-14%-26596880.896-25%-17034552.400-52%
Usd Revenue----0%-0%-0%33161.915-100%
Usd Total Gains Per Share--0.0390.0390%0.003+1327%0.012+215%0.014+183%
 EOD+2 -3MRQTTM+0 -0YOY+22 -125Y+20 -1410Y+20 -16

3.2. Fundamental Score

Let's check the fundamental score of Advanced Oncotherapy Plc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.777
Price to Book Ratio (EOD)Between0-10.854
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.273
Current Ratio (MRQ)Greater than11.907
Debt to Asset Ratio (MRQ)Less than10.566
Debt to Equity Ratio (MRQ)Less than11.302
Return on Equity (MRQ)Greater than0.15-0.481
Return on Assets (MRQ)Greater than0.05-0.209
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Advanced Oncotherapy Plc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5017.031
Ma 20Greater thanMa 5011.150
Ma 50Greater thanMa 10013.651
Ma 100Greater thanMa 20017.398
OpenGreater thanClose9.750
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2017-12-312018-12-312019-12-312020-12-312021-12-31
Net Tangible Assets  2,287,14829,9002,317,049422,5992,739,648-123,8422,615,806-3,336,600-720,794



Latest Balance Sheet

Balance Sheet of 2021-12-31. Currency in GBP. All numbers in thousands.

Summary
Total Assets141,291
Total Liabilities79,921
Total Stockholder Equity61,369
 As reported
Total Liabilities 79,921
Total Stockholder Equity+ 61,369
Total Assets = 141,291

Assets

Total Assets141,291
Total Current Assets30,730
Long-term Assets30,730
Total Current Assets
Cash And Cash Equivalents 3,760
Net Receivables 643
Inventory 25,827
Total Current Assets  (as reported)30,730
Total Current Assets  (calculated)30,230
+/- 500
Long-term Assets
Property Plant Equipment 41,055
Intangible Assets 68,577
Long-term Assets Other 927
Long-term Assets  (as reported)110,560
Long-term Assets  (calculated)110,560
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities16,118
Long-term Liabilities63,803
Total Stockholder Equity61,369
Total Current Liabilities
Short-term Debt 10,771
Short Long Term Debt 10,025
Accounts payable 2,450
Other Current Liabilities 958
Total Current Liabilities  (as reported)16,118
Total Current Liabilities  (calculated)24,205
+/- 8,087
Long-term Liabilities
Other Liabilities 21,219
Deferred Long Term Liability 47,507
Long-term Liabilities  (as reported)63,803
Long-term Liabilities  (calculated)68,726
+/- 4,923
Total Stockholder Equity
Common Stock112,903
Retained Earnings -151,502
Other Stockholders Equity 99,968
Total Stockholder Equity (as reported)61,369
Total Stockholder Equity (calculated)61,369
+/-0
Other
Capital Stock112,903
Cash and Short Term Investments 3,760
Common Stock Shares Outstanding 288,981
Liabilities and Stockholders Equity 141,291
Net Debt 49,595
Net Invested Capital 81,777
Net Tangible Assets -7,208
Net Working Capital 14,612
Short Long Term Debt Total 53,355



Balance Sheet

Currency in GBP. All numbers in thousands.

 Trend2021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-31
> Total Assets 
29,165
30,627
36,191
45,579
60,720
60,958
36,882
7,074
5,637
10,752
14,466
30,739
37,670
45,400
59,450
110,822
122,293
141,291
141,291122,293110,82259,45045,40037,67030,73914,46610,7525,6377,07436,88260,95860,72045,57936,19130,62729,165
   > Total Current Assets 
8,197
7,336
2,889
665
2,985
781
2,698
1,463
1,510
1,383
3,169
16,682
12,541
12,501
13,678
22,193
26,341
30,730
30,73026,34122,19313,67812,50112,54116,6823,1691,3831,5101,4632,6987812,9856652,8897,3368,197
       Cash And Cash Equivalents 
7,932
6,955
2,322
119
2,519
269
148
24
58
149
1,465
8,958
1,449
56
1,013
2,735
1,817
3,760
3,7601,8172,7351,013561,4498,9581,46514958241482692,5191192,3226,9557,932
       Net Receivables 
0
0
0
0
0
0
0
0
0
1,108
467
2,899
3,301
2,954
894
2,125
661
643
6436612,1258942,9543,3012,8994671,108000000000
       Inventory 
1
1
0
0
0
0
0
0
0
37
1,112
4,418
7,438
7,629
10,014
15,048
22,138
25,827
25,82722,13815,04810,0147,6297,4384,4181,11237000000011
   > Long-term Assets 
20,968
23,291
33,302
44,914
57,735
60,177
34,184
5,611
4,127
9,369
11,297
14,056
25,129
32,900
45,773
88,630
95,952
110,560
110,56095,95288,63045,77332,90025,12914,05611,2979,3694,1275,61134,18460,17757,73544,91433,30223,29120,968
       Property Plant Equipment 
20,612
21,539
30,050
42,965
55,983
60,178
34,184
5,444
205
2,673
2,079
1,312
1,774
1,181
8,173
38,531
38,148
41,055
41,05538,14838,5318,1731,1811,7741,3122,0792,6732055,44434,18460,17855,98342,96530,05021,53920,612
       Goodwill 
0
279
1,752
1,752
1,752
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000001,7521,7521,7522790
       Long Term Investments 
0
0
0
0
0
0
0
0
0
6
0
0
0
0
0
0
0
0
000000006000000000
       Intangible Assets 
356
1,752
1,752
1,950
1,752
0
0
0
0
6,690
9,218
12,744
23,355
30,570
40,165
49,183
56,869
68,577
68,57756,86949,18340,16530,57023,35512,7449,2186,69000001,7521,9501,7521,752356
       Other Assets 
0
30
1,749
252
179
128
81
30
28
6,779
9,218
12,744
20,284
25,618
30,551
34,560
39,820
927
92739,82034,56030,55125,61820,28412,7449,2186,7792830811281792521,749300
> Total Liabilities 
17,604
19,464
22,813
30,649
46,810
49,444
29,729
6,596
5,776
5,386
3,334
3,459
3,678
16,739
25,455
67,887
78,151
79,921
79,92178,15167,88725,45516,7393,6783,4593,3345,3865,7766,59629,72949,44446,81030,64922,81319,46417,604
   > Total Current Liabilities 
1,023
1,171
1,532
3,275
6,379
11,661
10,001
6,596
5,776
5,386
3,334
3,459
3,678
16,739
8,955
6,476
19,209
16,118
16,11819,2096,4768,95516,7393,6783,4593,3345,3865,7766,59610,00111,6616,3793,2751,5321,1711,023
       Short-term Debt 
366
355
341
2,393
4,438
9,207
7,383
3,802
3,804
3,190
988
1,000
543
9,247
3,000
1,595
12,771
10,771
10,77112,7711,5953,0009,2475431,0009883,1903,8043,8027,3839,2074,4382,393341355366
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
3,190
988
1,000
543
9,247
3,000
0
10,039
10,025
10,02510,03903,0009,2475431,0009883,190000000000
       Accounts payable 
0
108
139
205
441
349
1,283
1,623
957
723
532
342
1,576
4,032
2,776
1,854
1,598
2,450
2,4501,5981,8542,7764,0321,5763425327239571,6231,2833494412051391080
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
725
836
766
402
3,459
2,440
2,748
3,482
958
9583,4822,7482,4403,459402766836725000000000
   > Long-term Liabilities 
16,581
18,293
21,281
27,374
40,431
37,783
19,728
0
0
0
0
0
0
0
16,500
61,411
58,941
63,803
63,80358,94161,41116,500000000019,72837,78340,43127,37421,28118,29316,581
       Other Liabilities 
0
570
1,755
677
1,500
2,105
1,335
1,171
1,015
1,474
1,814
2,117
1,558
3,459
16,500
16,500
21,078
21,219
21,21921,07816,50016,5003,4591,5582,1171,8141,4741,0151,1711,3352,1051,5006771,7555700
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
8,233
9,218
12,744
20,284
24,780
29,340
33,645
38,885
47,507
47,50738,88533,64529,34024,78020,28412,7449,2188,233000000000
> Total Stockholder Equity
0
11,243
13,378
14,801
13,734
11,269
7,021
479
0
5,365
11,132
27,280
33,993
28,662
33,995
42,935
44,142
61,369
61,36944,14242,93533,99528,66233,99327,28011,1325,36504797,02111,26913,73414,80113,37811,2430
   Common Stock
0
11,745
768
768
768
768
768
768
2,594
6,044
10,284
14,183
18,117
20,234
42,392
61,106
83,360
112,903
112,90383,36061,10642,39220,23418,11714,18310,2846,0442,59476876876876876876811,7450
   Retained Earnings Total Equity000000000000000000
   Accumulated Other Comprehensive Income 
-9
-76
372
41
-75
-96
-26,099
-122
0
-82
-199
-41
-367
-710
-1,152
-3,143
0
0
00-3,143-1,152-710-367-41-199-820-122-26,099-96-7541372-76-9
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
43,118
43,259
50,724
60,452
61,443
0
061,44360,45250,72443,25943,118000000000000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
13,591
13,352
14,001
16,822
66,862
71,565
83,476
83,049
99,968
99,96883,04983,47671,56566,86216,82214,00113,35213,591000000000



Balance Sheet

Currency in GBP. All numbers in thousands.




Cash Flow

Currency in GBP. All numbers in thousands.




Income Statement

Currency in GBP. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-23,737
Operating Income-23,737-23,737
 
Operating Expense (+$)
Research Development-
Selling General Administrative23,737
Selling And Marketing Expenses-
Operating Expense23,73723,737
 
Net Interest Income (+$)
Interest Income0
Interest Expense-5,062
Net Interest Income-5,756-5,062
 
Pretax Income (+$)
Operating Income-23,737
Net Interest Income-5,756
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-29,493-17,981
EBIT - interestExpense = -29,493
-29,493
-24,431
Interest Expense5,062
Earnings Before Interest and Taxes (ebit)-24,431-24,431
Earnings Before Interest and Taxes (ebitda)-22,092
 
After tax Income (+$)
Income Before Tax-29,493
Tax Provision-0
Net Income From Continuing Ops-29,493-29,493
Net Income-29,493
Net Income Applicable To Common Shares-29,493
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses23,737
Total Other Income/Expenses Net-5,7565,756
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications